Study on protective effect of cyproheptadine on non-alcoholic fatty liver disease induced by dexamethasone in rats

Bing WANG,Yue-rong ZHU,Rui-ning YANG,Qi-long DING,Hong QIU
DOI: https://doi.org/10.13699/j.cnki.1001-6821.2015.07.008
2015-01-01
Abstract:Objective To investigate the effects of cyproheptadine on dexamethasone ( DEX ) -induced non -alcoholic fatty liver disease ( NAFLD ) in rats.Methods SD rats were divided randomly into 5 groups: normal group , model group with high , low dosage ( 2.5 , 1.0 mg· kg-1 ) DEX, high, low dosage (5.0 mg · kg -1 ) cyproheptadine treatment groups.Two weeks later after administration , all rats were killed.Body weight and liver weight of rats were measured.Level of serum liver function and lipoid index, glucose (GLU), free fatty acids ( FFA ) , fasting blood insulin ( FINS ) , adrenocorticotropic hormone ( ACTH) and corticosterone ( CORT) were detected.Rat primary hepato-cytes were isolated and treated with different concentration of DEX and cyproheptadine.The fatty droplets in cells were observed by oil red O staining under electron microscope.GLU in culture supernatant , intrace-llular trigly-ceride ( TG) and FFA levels were detected.Results DEX can cause disorders of glucose and lipid metabolism in rats.The level of alanine transarninase (ALT), aspartate aminotransferas (AST), blood fat, fasting blood glucose and insulin were higher than that of normal group.The hypothalamic pituitary adrenal ( HPA) axis was excessive ac-tivated and the level of ACTH and CORT were increased.While cyproheptadine can reduce the reactivity of HPA axis , improve glucose and lipid metabolism in rats.Similar results were obtained in the rat hepatocyte model tests.Conclusion Cyproheptadine can improve NAFLD induced by DEX in rats through the intervention of the HPA axis.
What problem does this paper attempt to address?